Stemcell Technologies Stemcell Technologies 25 Years

HUB & STEMCELL Organoids Virtual Mini-Symposium

Register Now
Join us on May 27 for a virtual mini-symposium with Hubrecht Organoid Technology and STEMCELL Technologies.

Join us on May 27 for a virtual mini-symposium with Hubrecht Organoid Technology and STEMCELL Technologies.

Stay connected to your colleagues and research by participating in our virtual mini-symposium co-hosted with Hubrecht Organoid Technology (HUB) and moderated by STEMCELL's product manager, Dr. Angela Zhang. Hear about the latest applications of epithelial organoid model systems, including their roles in investigating COVID-19, and participate in a live Q&A session with the speakers following the presentations. Have burning questions already? Submit them now with your registration form.

Date and Time:

Wednesday, May 27, 2020
8 a.m. PDT | 3 p.m. UTC | 5 p.m. CET

If you are unable to attend the live webinar, please register and a link will be sent to you with the recorded version.

  • Applications of intestinal organoids in precision medicine diagnostics
  • Case Study: The impacts of organoids in cancer and cystic fibrosis
  • Applications of organoids as model systems in fundamental research
  • Case Study: Development of snake venom gland organoids
  • Applications of organoids for studying infectious disease
  • Case Study: Organoids and COVID-19
Dr. Robert Vries
CEO, Hubrecht Organoid Technology (HUB)

Robert Vries received his PhD in Biochemistry from the Leiden University Center studying the molecular basis of oncogenic transformation. He continued his scientific career as a postdoctoral fellow at Stanford University. Upon his return to the Netherlands, he joined Hans Clevers’s group at the Hubrecht Institute studying adult stem cells. During this time, Dr. Vries was part of the team that developed the groundbreaking technology allowing the expansion of adult stem cells in vitro. The so-called organoid technology became the basis of the company Hubrecht Organoid Technology (HUB).

Dr. Sylvia Boj
CRO, Hubrecht Organoid Technology (HUB)

Sylvia Boj received her PhD in 2006 at the University of Barcelona, Spain, for her work at IDIBAPS on functional genetic analysis of MODY genes in pancreatic beta cells. She subsequently joined the Hubrecht Institute on a long-term EMBO fellowship. In the laboratory of Prof. Hans Clevers, she first studied the role of TCF7L2 in regulating metabolism. Then, she established an in vitro organoid model for human pancreatic cancers. In 2014, she moved to Hubrecht Organoid Technology as a group leader for the Cystic Fibrosis and Cancer programs. In 2016, she became Scientific Director of HUB, with the ultimate goal of transferring scientific advances in the organoid technology to the development of new drugs.

Dr. Ryan Conder
Associate Director, Gastrointestinal Biology, STEMCELL Technologies

Ryan Conder is the Associate Director of Gastrointestinal Biology at STEMCELL Technologies. He obtained his PhD in molecular biology and biochemistry from Simon Fraser University studying epithelial cell polarity in the group of Dr. Nicholas Harden and performed his postdoctoral research at IMBA in the group of Dr. Juergen Knoblich, identifying mechanisms of asymmetric cell division of intestinal stem cells. After spending time as a visiting scientist in the lab of Dr. Hans Clevers, he established the organoid portfolio at STEMCELL Technologies.